Research
Dabigatran etexilate versus warfarin in management of non-valvular atrial fibrillation in UK context: quantitative benefit-harm and economic analyses
BMJ 2011; 343 doi: https://doi.org/10.1136/bmj.d6333 (Published 31 October 2011) Cite this as: BMJ 2011;343:d6333
Data supplement
Web Extra
Extra material supplied by the author
Files in this Data Supplement:
Web Extra
Extra material supplied by the author
Files in this Data Supplement:
Related articles
- Editorial Published: 31 October 2011; BMJ 343 doi:10.1136/bmj.d6980
- News Published: 15 January 2013; BMJ 346 doi:10.1136/bmj.f303
See more
- Prescribing parkrun: medicalising a walk in the parkBMJ April 08, 2025, 389 r670; DOI: https://doi.org/10.1136/bmj.r670
- GPs can prescribe tirzepatide to priority patient groups from JuneBMJ April 02, 2025, 389 r665; DOI: https://doi.org/10.1136/bmj.r665
- Exercise referral rates for patients with risk of cardiovascular disease vary widely across England, study reportsBMJ February 12, 2025, 388 r287; DOI: https://doi.org/10.1136/bmj.r287
- Cardiovascular disease: Just one in 12 eligible people had health check last year, watchdog findsBMJ November 13, 2024, 387 q2518; DOI: https://doi.org/10.1136/bmj.q2518
- Semaglutide’s CVD indication could cost US Medicare $145bn extra a yearBMJ August 28, 2024, 386 q1878; DOI: https://doi.org/10.1136/bmj.q1878
Cited by...
- Cardiac rehabilitation for heart failure and atrial fibrillation: a propensity- matched study
- Economic evaluation of direct oral anticoagulants (DOACs) versus vitamin K antagonists (VKAs) for stroke prevention in patients with atrial fibrillation: a systematic review and meta-analysis
- Cost-Effectiveness of Oral Anticoagulants for Ischemic Stroke Prophylaxis Among Nonvalvular Atrial Fibrillation Patients
- Warfarin treatment among Finnish patients with atrial fibrillation: retrospective registry study based on primary healthcare data
- Cost-Effectiveness of Apixaban, Dabigatran, Rivaroxaban, and Warfarin for Stroke Prevention in Atrial Fibrillation
- Oral Antithrombotic Agents for the Prevention of Stroke in Nonvalvular Atrial Fibrillation: A Science Advisory for Healthcare Professionals From the American Heart Association/American Stroke Association
- Nonvitamin-K-Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation and Previous Stroke or Transient Ischemic Attack: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
- An introduction to the methods of cost-effectiveness analysis
- Critique of Apixaban Versus Warfarin in Patients With Atrial Fibrillation
- Take real world issues into account
- When Is Dabigatran More Cost-Effective Than Warfarin?
- Cost of dabigatran for atrial fibrillation